<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448019</url>
  </required_header>
  <id_info>
    <org_study_id>MDACC-2005-0992</org_study_id>
    <secondary_id>NCI-2010-00591</secondary_id>
    <nct_id>NCT00448019</nct_id>
  </id_info>
  <brief_title>FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of fludarabine,
      cyclophosphamide, rituximab, and bevacizumab is effective in treating chronic lymphocytic
      leukemia in patients who have already been treated with chemotherapy. The safety of this
      treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the study, you will have up to 6 &quot;cycles&quot; of treatment. A cycle is made up of
      treatment with the study drugs for 3-4 days and then about 3-1/2 weeks (25 days) of no
      treatment (about 4 weeks total). Treatment with the study drugs will be given for 4 days in a
      row on the first cycle, and 3 days in a row on Cycles 2-6. On Day 1 of each cycle, you will
      receive rituximab through a needle in a vein. On Cycle 1, since it is your first exposure to
      rituximab, it must be given slowly, so it may take 6-8 hours to complete. On the cycles after
      that, it can be given more rapidly, over 3-4 hours. Cyclophosphamide and fludarabine will be
      given separately through a needle in a vein on Days 2-4 of Cycle 1 and Days 1-3 of Cycles
      2-6. Cyclophosphamide and fludarabine will each be given over 30 minutes. Bevacizumab will be
      given through a needle in a vein over 90 minutes on Day 3 of Cycle 1. If it is well
      tolerated, the next dose of Bevacizumab will be given over 60 minutes on Day 2 of Cycle 2. If
      the Cycle 2 dose is well tolerated, the next doses of Bevacizumab will be given over 30
      minutes on Day 2 of Cycles 2-6. In addition to the study drugs, you may also be given fluids
      by vein to help flush the kidneys, to help prevent possible kidney damage. You may receive up
      to 6 cycles of treatment. Treatment will be given on an outpatient basis. The injections for
      each daily treatment visit should take less than 6 hours.

      Up to 66 patients will take part in the study. All will be enrolled at M.D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) Rate</measure>
    <time_frame>Baseline up to 5 years</time_frame>
    <description>Progression free survival (PFS) was defined as the time from the start of treatment to progression, which included treatment failure, relapse, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete or Partial Response to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated Chronic Lymphocytic Leukemia (CLL)</measure>
    <time_frame>Response assessed after three 4-week courses and after six courses, up to 24 weeks</time_frame>
    <description>Response criteria for Complete response (CR) - Nodes: None; Liver/Spleen Size: Not palpable; Symptoms: None; polymorphonuclear leukocytes (PMN): &gt;1,500/μl; Platelets &gt;100,000/μl; Hemoglobin (untransfused): &gt;11,0 g/dl; Lymphocytes: &lt;4,000/μl; Bone Marrow aspirate: &lt;30% lymphocytes; Biopsy: No lymphocyte infiltrate; and for Partial Response (PR), Nodes: &gt;/= 50% decrease; Liver/Spleen Size: &gt;/= 50% decrease; Symptoms: None; Platelets &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused): &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes: &gt;50% decrease; Biopsy: &lt;30% lymphocytes with residual disease on biopsy for nodular PR (NPR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated CLL</measure>
    <time_frame>Response assessed after three 4-week courses and after six courses, up to 24 weeks</time_frame>
    <description>ORR defined as CR and PR response where response criteria for Complete response (CR) - Nodes: None; Liver/Spleen Size: Not palpable; Symptoms: None; polymorphonuclear leukocytes (PMN): &gt;1,500/μl; Platelets &gt;100,000/μl; Hemoglobin (untransfused): &gt;11,0 g/dl; Lymphocytes: &lt;4,000/μl; Bone Marrow aspirate: &lt;30% lymphocytes; Biopsy: No lymphocyte infiltrate; and for Partial Response (PR), Nodes: &gt;/= 50% decrease; Liver/Spleen Size: &gt;/= 50% decrease; Symptoms: None; Platelets &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused): &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes: &gt;50% decrease; Biopsy: &lt;30% lymphocytes with residual disease on biopsy for nodular PR (NPR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FCR + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2 IV over 30 minutes daily for 3 days</description>
    <arm_group_label>FCR + Bevacizumab</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>250 mg/m^2 IV over 30 minutes daily for 3 days</description>
    <arm_group_label>FCR + Bevacizumab</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m^2 IV 30-minute infusion.</description>
    <arm_group_label>FCR + Bevacizumab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/Kg IV on Day 3, course 1 over 30-90 minutes</description>
    <arm_group_label>FCR + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of B-cell CLL

          -  Relapsed, fludarabine-sensitive (duration of response &gt; 6 months as assessed by prior
             treating physician) or fludarabine-naive patients

          -  Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as
             evidenced by rapid doubling of peripheral lymphocyte count, progressive
             lymphadenopathy, progressive splenomegaly, or B symptoms.

          -  Prestudy WHO Performance Status &lt;/= 2.

          -  Signed, written Institutional Review Board (IRB)approved informed consent.

          -  Men and women of reproductive potential must agree to follow accepted birth control
             methods during treatment and for 3 months after completion of treatment.

          -  Acceptable liver function: Bilirubin &lt;/= 2.0 mg/dL (26 umol/L), AST (SGOT) and/or ALT
             (SGPT) &lt;/= 2 times upper limit of normal.

          -  Acceptable hematologic status: Platelet count &gt;/= 50 x 10^9/L., absolute neutrophil
             count (ANC) &gt;/= 1 x 10^9/L.

          -  Acceptable renal function: Serum creatinine &lt;/= 2.0 mg/dL

        Exclusion Criteria:

          -  Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other
             investigational therapy within 4 weeks prior to Study Day 1.

          -  Known infection with HIV, hepatitis B, or hepatitis C

          -  Transformation to aggressive B-cell malignancy (e.g., large B-cell lymphoma, Richter's
             Syndrome, or prolymphocyte leukemia [PLL]).

          -  Patients with secondary malignancy requiring active treatment (except hormonal
             therapy).

          -  Active uncontrolled bacterial, viral, or fungal infections.

          -  New York Heart Association Class II-IV cardiac disease or myocardial infarction within
             the past 6 months prior to Study Day 1.

          -  Pregnant or currently breast-feeding.

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study other than a Genentech-sponsored
             bevacizumab cancer study.

          -  Blood pressure of &gt; 150/100 mmHg

          -  Unstable angina

          -  History of stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1, anticipation of need for major surgical procedure during the course of
             the study.

          -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
             prior to Day 1.

          -  Urine protein:creatinine ratio &gt;/= 1.0 at screening.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 1.

          -  Serious, non-healing wound, ulcer, or bone fracture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <results_reference>
    <citation>Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15;120(22):3494-501. doi: 10.1002/cncr.28910. Epub 2014 Jul 15.</citation>
    <PMID>25043749</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2007</study_first_posted>
  <results_first_submitted>July 13, 2015</results_first_submitted>
  <results_first_submitted_qc>October 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2015</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 23, 2007 to November 17, 2010. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FCR + Bevacizumab</title>
          <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance Issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two participants included in the study demographics were registered but withdrew prior to receiving treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>FCR + Bevacizumab</title>
          <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="39" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) Rate</title>
        <description>Progression free survival (PFS) was defined as the time from the start of treatment to progression, which included treatment failure, relapse, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Baseline up to 5 years</time_frame>
        <population>Five participants of the 62 treated participants were not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>FCR + Bevacizumab</title>
            <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) Rate</title>
          <description>Progression free survival (PFS) was defined as the time from the start of treatment to progression, which included treatment failure, relapse, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>Five participants of the 62 treated participants were not evaluable for response.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="1" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete or Partial Response to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated Chronic Lymphocytic Leukemia (CLL)</title>
        <description>Response criteria for Complete response (CR) - Nodes: None; Liver/Spleen Size: Not palpable; Symptoms: None; polymorphonuclear leukocytes (PMN): &gt;1,500/μl; Platelets &gt;100,000/μl; Hemoglobin (untransfused): &gt;11,0 g/dl; Lymphocytes: &lt;4,000/μl; Bone Marrow aspirate: &lt;30% lymphocytes; Biopsy: No lymphocyte infiltrate; and for Partial Response (PR), Nodes: &gt;/= 50% decrease; Liver/Spleen Size: &gt;/= 50% decrease; Symptoms: None; Platelets &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused): &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes: &gt;50% decrease; Biopsy: &lt;30% lymphocytes with residual disease on biopsy for nodular PR (NPR).</description>
        <time_frame>Response assessed after three 4-week courses and after six courses, up to 24 weeks</time_frame>
        <population>Five participants of the 62 treated participants were not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>FCR + Bevacizumab</title>
            <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete or Partial Response to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated Chronic Lymphocytic Leukemia (CLL)</title>
          <description>Response criteria for Complete response (CR) - Nodes: None; Liver/Spleen Size: Not palpable; Symptoms: None; polymorphonuclear leukocytes (PMN): &gt;1,500/μl; Platelets &gt;100,000/μl; Hemoglobin (untransfused): &gt;11,0 g/dl; Lymphocytes: &lt;4,000/μl; Bone Marrow aspirate: &lt;30% lymphocytes; Biopsy: No lymphocyte infiltrate; and for Partial Response (PR), Nodes: &gt;/= 50% decrease; Liver/Spleen Size: &gt;/= 50% decrease; Symptoms: None; Platelets &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused): &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes: &gt;50% decrease; Biopsy: &lt;30% lymphocytes with residual disease on biopsy for nodular PR (NPR).</description>
          <population>Five participants of the 62 treated participants were not evaluable for response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nodular Partial Response (NPR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR) to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated CLL</title>
        <description>ORR defined as CR and PR response where response criteria for Complete response (CR) - Nodes: None; Liver/Spleen Size: Not palpable; Symptoms: None; polymorphonuclear leukocytes (PMN): &gt;1,500/μl; Platelets &gt;100,000/μl; Hemoglobin (untransfused): &gt;11,0 g/dl; Lymphocytes: &lt;4,000/μl; Bone Marrow aspirate: &lt;30% lymphocytes; Biopsy: No lymphocyte infiltrate; and for Partial Response (PR), Nodes: &gt;/= 50% decrease; Liver/Spleen Size: &gt;/= 50% decrease; Symptoms: None; Platelets &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused): &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes: &gt;50% decrease; Biopsy: &lt;30% lymphocytes with residual disease on biopsy for nodular PR (NPR).</description>
        <time_frame>Response assessed after three 4-week courses and after six courses, up to 24 weeks</time_frame>
        <population>Five participants of the 62 treated participants were not evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>FCR + Bevacizumab</title>
            <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated CLL</title>
          <description>ORR defined as CR and PR response where response criteria for Complete response (CR) - Nodes: None; Liver/Spleen Size: Not palpable; Symptoms: None; polymorphonuclear leukocytes (PMN): &gt;1,500/μl; Platelets &gt;100,000/μl; Hemoglobin (untransfused): &gt;11,0 g/dl; Lymphocytes: &lt;4,000/μl; Bone Marrow aspirate: &lt;30% lymphocytes; Biopsy: No lymphocyte infiltrate; and for Partial Response (PR), Nodes: &gt;/= 50% decrease; Liver/Spleen Size: &gt;/= 50% decrease; Symptoms: None; Platelets &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused): &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes: &gt;50% decrease; Biopsy: &lt;30% lymphocytes with residual disease on biopsy for nodular PR (NPR).</description>
          <population>Five participants of the 62 treated participants were not evaluable for response.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants evaluated for adverse events at each study visit for study duration, up to six courses of 4 weeks. Overall collection period: May 2011 to September 2014.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FCR + Bevacizumab</title>
          <description>FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Tumor lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>MD Anderson Cancer Center Leukemia Department</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

